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Abstract
Background: Neuropeptide Y (NPY) is emerging as a modulator of communication between the brain and the
immune system. However, in spite of increasing evidence that supports a role for NPY in the modulation of
microglial cell responses to inflammatory conditions, there is no consistent information regarding the action of
NPY on microglial phagocytic activity, a vital component of the inflammatory response in brain injury. Taking this
into consideration, we sought to assess a potential new role for NPY as a modulator of phagocytosis by microglial
cells.
Methods: The N9 murine microglial cell line was used to evaluate the role of NPY in phagocytosis. For that
purpose, an IgG-opsonized latex bead assay was performed in the presence of lipopolysaccharide (LPS) and an
interleukin-1b (IL-1b) challenge, and upon NPY treatment. A pharmacological approach using NPY receptor
agonists and antagonists followed to uncover which NPY receptor was involved. Moreover, western blotting and
immunocytochemical studies were performed to evaluate expression of p38 mitogen-activated protein kinase
(MAPK) and heat shock protein 27 (HSP27), in an inflammatory context, upon NPY treatment.
Results: Here, we show that NPY inhibits phagocytosis of opsonized latex beads and inhibits actin cytoskeleton
reorganization triggered by LPS stimulation. Co-stimulation of microglia with LPS and adenosine triphosphate also
resulted in increased phagocytosis, an effect inhibited by an interleukin-1 receptor antagonist, suggesting
involvement of IL-1b signaling. Furthermore, direct application of LPS or IL-1b activated downstream signaling
molecules, including p38 MAPK and HSP27, and these effects were inhibited by NPY. Moreover, we also observed
that the inhibitory effect of NPY on phagocytosis was mediated via Y1 receptor activation.
Conclusions: Altogether, we have identified a novel role for NPY in the regulation of microglial phagocytic
properties, in an inflammatory context.
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Background
Microglia are the resident immunocompetent cells of
the central nervous system (CNS), responsible for
mounting appropriate responses to injuries such as
trauma, ischemia, brain tumors and neurodegenerative
diseases that target the brain parenchyma [1,2]. More-
over, microglia display a wide range of receptors that
enable the recognition of pathogens or cell damage-
related antigens, thereby promoting phagocytosis and
removal of cell debris [3]. Phagocytosis is a coordinated
process, triggered by environmental signals that requires
a dynamic actin cytoskeleton rearrangement and a
plethora of receptor signaling pathways [4].
The role of microglia in inflammation has been
experimentally dissected using lipopolysaccharide (LPS)
stimulation, which mimics Gram-negative infection,
through the activation of Toll-like receptor 4 (TLR4).
While microglia randomly scan the healthy brain par-
enchyma, activated cells undergo significant morpholo-
gical changes and an ensuing targeted movement
toward the site of injury, where they release both neuro-
trophic and neurotoxic factors [2,5]. Amongst the
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any medium, provided the original work is properly cited.inflammatory mediators initially secreted, interleukin-1b
(IL-1b) is particularly relevant given its involvement in
excitotoxicity, ischemia, brain trauma and cell death
[6-8]. Recently, we have described a chemokinetic effect
of IL-1b on microglial motility, whereby IL-1b stimu-
lates microglial motility with involvement of p38 MAPK
signaling [9].
Growing evidence supports involvement of neuropep-
tide Y (NPY) in the modulation of the immune system,
with effects on macrophage, B and T cell function; as
well as dendritic cell stimulatory ability [10]. However,
i t sr o l ei np h a g o c y t o s i sr e m ains controversial. Neuro-
peptide Y (NPY) is widely distributed within the periph-
eral and central nervous systems and has well defined
physiological roles that include regulation of blood pres-
sure, circadian rhythms, feeding behavior, memory pro-
cessing and learning [11].
In this context, our objective was to unravel the role
of NPY in the modulation of Fc receptor-mediated pha-
gocytosis (the best characterized phagocytic receptor) by
activated microglial cells during inflammation. Micro-
glial cells have specific signaling systems that regulate
rapid rearrangement of the actin cytoskeleton enabling
the cell to phagocytose when needed. Here, we report
an inhibitory effect of NPY, acting via Y1 receptors, on
IL-1b-stimulated phagocytosis, a process accompanied
by p38 MAPK and HSP27 activation. Our results high-
light the modulation of phagocytosis as part of the puta-
tive anti-inflammatory role of NPY, supporting the
importance of this neuropeptide in the regulation of
important microglial responses to danger signals in the
brain.
Methods
Cell line cultures
A murine N9 microglia cell line (a kind gift from Pro-
fessor Claudia Verderio, CNR Institute of Neuroscience,
Cellular and Molecular Pharmacology, Milan, Italy) was
g r o w ni nR P M Im e d i u ms u p p l e m e n t e dw i t h3 0m M
glucose (Sigma, St. Louis, MO, USA), 100 U/ml penicil-
lin and 100 μg/ml streptomycin (GIBCO, Invitrogen,
Barcelona, Spain). Cells were kept at 37°C in a 95%
atmospheric air and 5% CO2 humidified atmosphere.
Numbers of viable cells were evaluated by counting try-
pan blue-excluding cells that were then plated at a den-
s i t yo f2×1 0
4 cells per well in 24-well trays, or plated
at a density of 5 × 10
5 cells per well in 6-well trays (for
remaining experiments).
Cell treatment for phagocytosis studies included the
following incubation setup: NPY (human, rat/amidated
sequence) (1 μM) (Bachem, Bubendorf, Switzerland),
LPS (100 ng/ml) (Sigma), ATP (1 mM) (Sigma), IL-1b
(1.5 ng/ml) (R&D System, Minneapolis, MN, USA), IL-
1ra (150 ng/ml) (R&D Systems), SB239063 (chemically
synthesized) (20 μM) (Tocris, Bristol, UK), Y1 receptor
agonist [Leu31, Pro34]NPY (porcine, amidated
sequence) (1 μM) (Bachem), Y1 receptor antagonist
BIBP3226 (1 μM, in water) (Bachem), Y2 receptor
antagonist BIIE0246 (1 μM, in 0.06% DMSO) (Tocris)
and Y5 receptor antagonist L-152,804 (1 μM, in 0.2%
DMSO) (Tocris), for 6 hrs. ATP, SB239063 and all
receptor antagonists were added 30 min prior to cell
treatment and maintained during the course of
experiments.
Generation of an N9 murine microglia cell line stably
expressing human FcgRIIA
The N9 microglia cell line expresses a variety of Fc
receptors. To overcome this issue, and due to the
absence of good antibodies against Fc receptors, we
decided to constitutively express human FcgRIIA tagged
with c-myc. The protocol for generation of N9 cells
expressing FcgRIIA, retrovirus production, cell infection
and selection was adopted from [12,13]. Briefly, human
FcgRIIA tagged with C-terminal myc-His6 was sub-
cloned into the retroviral vector pBABE-puro, which
contains a resistance gene to puromycin. The viruses
were produced by tranfecting the human Phoenix gag-
pol packaging cell line with the retroviral plasmid
together with incorporation of the vesicular stomatitis
virus G protein. Because of the incorporation of the
vesicular stomatitis virus G protein into the virus envel-
ope, these viral particles are able to infect almost any
dividing mammalian cell. For infection, 1.5 × 10
5 cells
were incubated with 1 ml of retrovirus, pseudotyped
with the VSV-G envelope protein, expressing the Fc-
receptor in the presence of 4 μg/ml polybrene (Sigma),
at 32°C. After 24 hrs of incubation, the medium was
changed and the infection procedure repeated. Twenty-
four hours later, cells were trypsinized and seeded into a
6-well tray in the presence of 7 μg/ml puromycin
(Sigma). Selection was done for another 48 hrs.
Phagocytosis assay
Beads were opsonized with rabbit IgG (1 μg/ml) (Sigma)
or with human IgG (0.5 μg/ml) (Sigma, St. Louis, MO,
USA) (for the phagocytic cup studies) under constant
agitation at 8 rpm, overnight at 4°C. Beads were then
resuspended in modified RPMI medium, without
NaHCO3, and distributed at a density of 1 × 10
5 beads
per well. After 40 min of incubation (or 20 min, for
phagocytic cup studies), cells were washed with PBS and
fixed with 4% paraformaldehyde (PFA). Extracellular
and/or adherent beads were labeled with secondary anti-
body Alexa Fluor 594 donkey anti-rabbit or with Cy5
donkey anti-human (Molecular Probes, Oregon, USA),
1: 500, in PBS. For each field, three photomicrographs
were acquired in order to capture stained nuclei (in
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total number of beads (differential interference contrast
image). The location of each bead was analyzed by com-
paring the three separate images simultaneously. Only
beads without fluorescent labeling were considered as
internalized particles. For nuclear labeling, cell prepara-
tions were stained with Hoechst 33342 (2 μg/ml) (Mole-
cular Probes) in PBS, for 5 min at room temperature
(RT). Coverslips were then mounted in Dako fluorescent
medium (Dakocytomation Inc., California, USA). Fluor-
escent images were acquired using an Axiovert 200 M
microscope, equipped with an AxiocamHRm and Plan-
ApoChromat 40 ×/1.30 oil objective (Göttingen,
Germany).
Immunocytochemistry
Cells were fixed with 4% PFA (Sigma) and unspecific
binding was prevented by incubating cells in a 3% BSA
and 0.3% Triton X-100 solution (all from Sigma) for 30
min, at RT. Cells were kept overnight at 4°C, in 0.3%
BSA and 0.1% Triton X-100 primary antibody solution,
then washed with PBS, and incubated for 1 hr at RT
with the corresponding secondary antibody.
Antibodies used were: rabbit polyclonal anti-phos-
phorylated HSP27 (1:400) (Cell Signaling Tech, Beverly,
MA, USA); mouse monoclonal anti-c-myc (1:2000) (Cell
Signaling Tech,); rat monoclonal anti-CD11b (1:1000)
(AbD Serotec, Oxford, UK); Alexa Fluor 594 goat anti-
rabbit; Alexa Fluor 488 donkey anti-rabbit; Alexa Fluor
594 donkey anti-mouse; Alexa Fluor 488 goat anti-rat
(all 1:200 in PBS, from Molecular Probes).
Membrane ruffling was observed using a marker for
filamentous actin, phalloidin. Cells were incubated for 2
hrs in phalloidin-Alexa Fluor 594 conjugate, 1:100
(Molecular Probes) in PBS, at RT, protected from light.
For nuclear labeling, cell preparations were stained
with Hoechst 33342 (2 μg/ml) (Molecular Probes,
Eugene, Oregon, USA) in PBS, for 5 min at RT and
mounted in Dakocytomation fluorescent medium
(Dakocytomation Inc., California, USA). Fluorescent
images were acquired using a confocal microscope, with
a Plan-ApoChromat 63 ×/1.40 oil objective (LSM 510
Meta, Carl Zeiss, Göttingen, Germany).
Western blotting
Cells were incubated with lysis cocktail solution (137
mM NaCl, 20 mM Tris-HCl, 1% Triton X-100, 10% gly-
cerol, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml
aprotinin, 1 μg/ml leupeptin, 0.5 mM sodium vanadate
(all from Sigma), pH 8.0). After gentle homogenization,
the total amount of protein was quantified using the
BCA method (Thermo Scientific, Rockford, USA). After-
wards, samples were loaded onto 10% acrylamide/bisa-
crilamide gels (BioRad, Hercules, CA, USA). Proteins
were separated by SDS-PAGE using a bicine/SDS
(Sigma) electrophoresis buffer (pH 8.3) and then trans-
ferred to PVDF membranes (Millipore) with a 0.45-μm
pore size, under the following conditions: 300 mA, 90
min at 4°C in a solution containing 10 mM CAPS
(Sigma) and 10% methanol (VWR International S.A.S.
France), pH 11.0) (protocol adapted from [14]). For
detection of phosphorylated proteins, membranes were
blocked in Tris-buffer saline (TBS) containing 5% BSA,
0.1% Tween
® 20 (Sigma) for 1 hr, at RT, and then incu-
bated overnight at 4°C with the primary antibody diluted
in blocking solution.
The following primary antibodies were used: rabbit
polyclonal anti-phosphorylated HSP27 (1:1000), rabbit
polyclonal anti-HSP27 (1:1000) (both from Cell Signal-
ing) and mouse monoclonal anti-c-myc (1:600) (Santa
Cruz Biotechnology Inc.). After rinsing three times with
TBS-T, membranes were incubated for 1 hr at RT with
an alkaline phosphatase-linked secondary antibody anti-
rabbit IgG 1:20,000 or anti-mouse IgG 1:10,000 in
blocking solution (GE Healthcare UK Limited, Buckin-
ghamshire, UK). Protein immunoreactive bands were
visualized in a Versa-Doc Imaging System (Model 3000,
BioRad Laboratories, CA, USA), after incubation of the
membranes with enhanced chemofluorescence reagent
(GE Healthcare UK Limited) for 5 min.
Data analysis
Statistical analysis was performed using GraphPad Prism
5.0 (GraphPad Software, San Diego, CA). Statistical sig-
nificance was considered relevant for p values < 0.05
using one-way analysis of variance followed by Bonfer-
roni post hoc test for comparison among experimental
settings and Dunnett post hoc test for comparison with
control condition. Data are presented as mean ± stan-
dard error of mean (SEM). For every immunocytochem-
ical analysis, 5 independent microscopy fields were
acquired per coverslip (about 50 cells per field). Every
experimental condition was tested in three sets of inde-
pendent experiments (n), unless stated otherwise, and
performed in duplicate.
Results
NPY inhibits Fc receptor-mediated phagocytosis by
microglial cells
The murine N9 microglia cell line was used to discern
the role of NPY in LPS-induced phagocytosis. LPS is a
component of Gram-negative bacterial outer membranes
and binds to the CD14/TLR4/MD2 receptor complex
present at the microglial cell membrane, triggering sev-
eral signaling cascades [15]. We have previously used
this cell line to dissect the effects of LPS over other
microglial physiological responses, such as production of
inflammatory mediators [e. g. nitric oxide (NO) and IL-
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Page 3 of 151b)] and migration/motility. We observed that NPY, act-
ing via the Y1 receptor, inhibited LPS-induced micro-
glial activation [9,16].
Prior to phagocytosis, microglial cells were challenged
with LPS (100 ng/ml) and/or NPY (1 μM) for 6 hrs.
IgG-opsonized latex beads were added at a density of 1
×1 0
5 p e rw e l la n da l l o w e dt ob ei n g e s t e df o r4 0m i n .
After fixation, non-ingested beads were immunolabeled
in order to distinguish extracellular and adherent parti-
cles from those internalized. Therefore, phagocytosed
beads were distinguished from non-phagocytosed beads
by means of fluorescent labeling (none versus red,
respectively) (Figure 1A). LPS significantly increased
bead phagocytosis, while NPY inhibited this effect
(meanCTR = 100 ± 29.46%; meanLPS = 730.50 ± 74.02%;
meanLPS+NPY = 250 ± 23.47%; meanNPY= 195.60 ±
79.83%; p < 0.001) (Figure 1B). In Figure 1A, representa-
tive photomicrographs illustrate the inhibitory effect of
NPY over LPS-stimulated microglia phagocytosis.
LPS-induced phagocytosis involves IL-1b signaling
LPS and ATP co-administration induces a massive
release of IL-1b [17-20]. We have previously shown that
murine N9 microglial cells release the biologically active
form of IL-1b upon LPS and ATP challenge [16]. LPS
activates TLR4, triggering several inflammatory
responses, while ATP exposure stimulates P2X7 recep-
tors, leading to opening of a non-selective pore that
allows massive calcium entry and, consequently, activa-
tion of interleukin converting enzyme (ICE) [21,22]. In
our study, LPS (100 ng/ml) plus ATP (1 mM) signifi-
cantly stimulated opsonized beads uptake (meanCTR =
100 ± 27.91%; meanLPS+ATP = 699.50 ± 58.33%; p <
0.001) (Figure 2). Interestingly, this effect was comple-
tely abolished by interleukin-1b receptor antagonist (IL-
1ra) treatment (150 ng/ml), suggesting involvement of
IL-1b in LPS-plus-ATP-induced microglial phagocytosis
(meanLPS+ATP = 699.50 ± 58.33%; meanLPS+ATP+IL-1ra =
113.90 ± 19.02%; p < 0.001). Accordingly, IL-1b (1.5 ng/
ml) significantly increased microglial cell phagocytosis,
which was also inhibited by exposure to IL-1ra (meanIL-
1b = 685.90 ± 36.37%; meanIL-1b+IL-1ra = 198 ± 37.10%; p
< 0.001) (Figure 2B). In Figure 2A, representative photo-
micrographs illustrate a stimulatory effect of IL-1b on
microglial phagocytosis, as well as LPS and ATP, and an
inhibitory effect of IL-1ra over these events.
NPY inhibits IL-1b-stimulated phagocytosis via Y1
receptor activation
In accordance with the previous experiments, microglial
cells were then treated with IL-1b (1.5 ng/ml) and NPY
(1 μM). As a result, we observed that NPY inhibited IL-
1b-induced phagocytosis (meanIL-1b = 685.90 ± 36.37%;
meanIL-1b+NPY = 115.40 ± 37.99%; p < 0.001) (Figure 3A
and 3B). Moreover, to assess through which receptor
NPY inhibits microglial phagocytic activity, cells were
treated with the Y1 receptor agonist [Leu
31,P r o
34]N P Y
(1 μM) or the Y1 receptor antagonist BIBP3226 (1 μM).
Y1 receptor activation resulted in inhibition of IL-1b-
induced phagocytosis while the Y1 receptor antagonist
blocked the effect induced by NPY (meanIL-1b+[Leu, Pro]
NPY = 213.70 ± 20.37%; meanIL-1b+NPY+BIBP3226 = 705.90
± 23.89%; p < 0.001). Involvement of the other main
NPY-stimulated receptors in brain was excluded using a
combination of selective antagonists for Y2 receptor
(BIIE0246, 1 μM) and for Y5 receptor (L152-804, 1 μM),
since, in the presence of both antagonists, NPY was still
able to inhibit phagocytosis (meanIL-1b+NPY+BIIE0246+L152-
804 = 135.70 ± 32.65%) (Figure 3A and 3B).
LPS-stimulated phagocytosis requires p38 signaling
We have previously observed that p38 MAPK signaling
pathway is activated during actin cytoskeletal assembly.
Moreover, p38 inhibition dampens this process. Accord-
ingly, we hypothesized that p38 was involved in phago-
cytosis, a very well coordinated process that requires
dynamic arrangement of actin filaments [4]. For that
matter, we decided to investigate whether the NPY inhi-
bitory effect on phagocytosis is caused by any visible
alterations in the reorganization of the actin cytoskele-
ton, using phalloidin staining. Cell morphology was
assessed using the labeling with the surface marker
CD11b, which is expressed by microglial cells [23] (Fig-
ure 4). Upon LPS challenge, actin (in red) actively poly-
merized and formed exuberant and flexible structures
named membrane ruffles; this feature can contribute, at
least in part, to the increased rate of phagocytosis.
Untreated cells or cells otherwise treated with NPY
mainly exhibited cortical actin. We would like to stress
that there was a huge reduction in membrane ruffles on
NPY-treated cells compared with LPS-treated cells (Fig-
ure 4). Thus, the effect of NPY on phagocytosis upon
LPS challenge can be attributed, at least partially, to
changes in actin cytoskeleton rearrangements. Accord-
ingly, in the presence of the p38 inhibitor SB239063 (20
μM), actin cytoskeleton morphology resembled that of
untreated or NPY-treated cells (Figure 4).
In addition, we observed that in the presence of the
p38 inhibitor, LPS-stimulated phagocytosis was reduced
and was similar to untreated cells (meanCTR = 100 ±
0.01%; meanLPS = 740.5 ± 246%; meanLPS+SB239063 =1 1 8
± 19.45%; meanSB239063 = 147.1 ± 63.81%; p < 0.05) (Fig-
ure 5A and 5B). Heat shock protein 27 (HSP27) is a
downstream target of p38, also implicated in the control
of actin polymerization [24]. Herein, we observed by
western blot and immunocytochemistry that both LPS
and IL-1b significantly induced HSP27 phosphorylation
(meanCTR = 100%; meanLPS =1 2 2 . 5±7 . 2 5 % ;m e a n IL-1b
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Page 4 of 15Figure 1 NPY inhibits bead phagocytosis by microglial cells. (A) Representative photomicrographs illustrate the inhibitory effect of NPY on
LPS-induced phagocytosis. (B) LPS (100 ng/ml) increased bead phagocytosis, while NPY (1 μM) inhibited this effect. Data are expressed as mean
± SEM (n = 3-5) and as a percentage of control (***p < 0.001, using Bonferroni’s Multiple Comparison Test). Scale bar 10 μm.
Ferreira et al. Journal of Neuroinflammation 2011, 8:169
http://www.jneuroinflammation.com/content/8/1/169
Page 5 of 15Figure 2 LPS-induced phagocytosis is mediated by IL-1b signaling. (A) Representative photomicrographs illustrate the inhibitory effect of IL-
1b, or LPS+ATP alone or with co-treatment with IL-1ra. (B) LPS (100 ng/ml) and ATP (1 mM) co-administration significantly induced bead
phagocytosis. This effect was prevented by IL-1ra application (150 ng/ml) suggesting involvement of IL-1b. Direct application of IL-1b (1.5 ng/ml)
increased phagocytosis and was completely inhibited by IL-1ra. Data are expressed as mean ± SEM (n = 3-5) and as a percentage of control
(***p < 0.001, using Bonferroni’s Multiple Comparison Test). Scale bar 10 μm.
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Page 6 of 15Figure 3 NPY inhibits IL-1b-induced phagocytosis via Y1 receptor activation. (A) Representative photomicrographs illustrate the inhibitory
effect of NPY acting via Y1 receptor on IL-1b-induced cell phagocytosis. (B) Microglial cells were stimulated with IL-1b (1.5 ng/ml) and treated
with NPY (1 μM). As NPY inhibited IL-1b-induced phagocytosis, a Y1 receptor agonist [Leu
31, Pro
34]NPY (1 μM) and a Y1 receptor antagonist
BIBP3226 (1 μM) were used to determine the effect of Y1R activation on IL-1b-induced phagocytosis. The involvement of other NPY receptors
was ruled out with the use of antagonists for the Y2 receptor (BIIE0246, 1 μM) and the Y5 receptor (L152-804, 1 μM). Data are expressed as mean
± SEM (n = 3-5) and as a percentage of control (***p < 0.001, using Bonferroni’s Multiple Comparison Test). Scale bar 10 μm.
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Page 7 of 15Figure 4 NPY inhibits LPS-induced actin cytoskeleton reorganization. Representative confocal photomicrographs were taken to assess the
role of LPS on rearrangement of the actin cytoskeleton. Microglial cells treated with LPS (100 ng/ml) showed significant membrane ruffling,
while NPY (1 μM) reduced this effect. Moreover, microglial cells treated with LPS (100 ng/ml), in the presence of SB239063, showed a
cytoskeleton rearrangement similar to that of untreated cells. Cells were stained for actin (in red), CD11b (in green) and Hoechst 33342 (nuclei in
blue). Scale bar 10 μm.
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Page 8 of 15Figure 5 LPS-stimulated phagocytosis requires p38 activation. (A) Representative photomicrographs depict involvement of p38 signaling in
LPS-induced phagocytosis. (B) Microglial cells were treated with LPS (100 ng/ml). Application of a p38 inhibitor, SB239063 (20 μM), significantly
inhibited LPS-induced phagocytosis. Data are expressed as mean ± SEM (n = 3) and as a percentage of control (*p < 0.05; **p < 0.01, using
Bonferroni’s Multiple Comparison Test). Scale bar 10 μm.
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Page 9 of 15Figure 6 NPY inhibits LPS- and IL-1b-induced HSP27 phosphorylation. (A) Densitometric quantification of western blots shows that
microglial cells, treated with LPS (100 ng/ml) or with IL-1b (1.5 ng/ml) showed increased levels of phosphorylated HSP27, while NPY (1 μM)
clearly inhibited this effect. Moreover, cells treated with the p38 inhibitor SB239063 (20 μM) showed decreased expression similar to that of
untreated cells. (B) Representative confocal photomicrographs demonstrate increased phosphorylation of HSP27 upon inflammatory challenge.
Cells were stained for phosphorylated HSP27 (in red), CD11b (in green) and Hoechst 33342 (nuclei in blue). Data are expressed as mean ± SEM
(n = 4-5) and as a percentage of control (*p < 0.05, using Bonferroni’s Multiple Comparison Test). Scale bar 10 μm.
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(SB239063) inhibited this effect (meanLPS+SB239063 = 93.8
± 9.21%; mean IL-1b+SB239063 =8 8 . 1 7±8 . 4 8 % ;p<0 . 0 5 ) ,
supporting the involvement of p38 signaling in HSP27
activation (Figure 6). Additionally, NPY inhibited LPS-
and IL-1b-induced HSP27 phosphorylation (meanLPS
+NPY =1 0 3 . 8±2 . 7 4 % ;m e a nIL-1b+NPY = 104.3 ± 13.58%;
meanNPY = 109.9 ± 8.13%; p < 0.05) (Figure 6A). In Fig-
ure 6B, HSP27 labeling (in red) is significantly increased
in LPS- and IL-1b-activated cells compared to untreated
cells. To visualize cell morphology, we labeled cells with
the surface marker CD11b, which is known to be
expressed by microglial cells [23].
Interestingly, in accordance with the increased expres-
sion of phosphorylated p38 and HSP27 in LPS or IL-1b-
treated cells, we also observed that HSP27 co-localized
with the actin cup surrounding beads in the process of
phagocytosis. HSP27 expression in the phagocytic cups
observed in LPS-treated cells was clearly potentiated
when compared to phagocytic cups in non-stimulated
cells (showing a faint but still present staining of
HSP27) (Figure 7).
NPY reduces FcgRIIA expression on LPS- and IL-1b-
stimulated microglia
To further evaluate the role of NPY on FcR-mediated
phagocytosis, we transfected N9 microglial cells in order
to stably expresses human FcgRIIA, a receptor mainly
involved in the phagocytosis of opsonized particles [25].
In that sense, we observed that upon LPS or IL-b chal-
lenge, the derived N9 microglia cell line significantly
increased FcgRIIA protein levels, quantified by western
blotting (meanCTR = 100 ± 0.01%; meanLPS = 128.30 ±
7.13%; meanIL-1b = 123.70 ± 7.69%; n = 4, p < 0.05)
(Figure 8A). In the presence of NPY, stimulated cells
displayed a reduction of FcgRIIA expression levels, indi-
cating that NPY may inhibit phagocytosis by decreasing
the level of receptors on the plasma membrane
(meanLPS+NPY = 97.72 ± 6.30%; meanIL-1b+NPY =9 3 . 8 1±
6.18%; n = 4, p < 0.05).
In addition, using immunocytochemistry, we observed
that both LPS and IL-b increased FcgRIIA expression
levels in microglial cells. Moreover, NPY treatment sig-
nificantly reduced FcgRIIA expression on either LPS- or
IL-b-stimulated cells, to levels similar to untreated cells
(Figure 8B).
Discussion
Microglial cells play a pivotal role in immunosurveillance
in the CNS, acting as resident macrophages in the brain
parenchyma [1,7,26,27]. In recent years, increasing evi-
dence has suggested that NPY is an important regulator of
immune system function, with different results obtained
concerning the role of this peptide in phagocytosis
[10,28-32]. In our study, we used an experimental model
of microglial phagocytic activity induced by lipopolysac-
charide (LPS) to evaluate the role of NPY on Fc receptor-
mediated phagocytosis. Microglial cells are constantly
prowling the brain environment and are able to efficiently
identify invading pathogens by expressing a vast array of
pattern recognition receptors, such as Toll-like receptors
(TLRs) [1,2]. Among the different members of the TLR
family, TLR4 is the best characterized. TLR4 recognizes
LPS, a component of the outer membrane of Gram-nega-
tive bacteria [33]. Importantly, LPS-induced phagocytosis
in macrophages requires TLR4 signaling since downregu-
lation of TLR4 expression by RNAi significantly compro-
mises the phagocytic activity of these cells [34].
Accordingly, we show that LPS significantly enhances
microglial Fc receptor-mediated phagocytosis while NPY,
via Y1 receptor activation, inhibits this effect. Moreover,
we observed that LPS-induced phagocytosis of IgG-opso-
nized beads is a process that occurs with the involvement
of IL-1b and downstream activation of the p38 mitogen-
activated protein kinase (MAPK) pathway.
In light of our previous results, showing involvement
of interleukin-1b (IL-1b) in LPS-stimulated microglial
cell activation and motility, we proposed to uncover a
role for IL-1b in LPS-stimulated phagocytosis. Accord-
ingly, LPS and ATP co-administration stimulated phago-
cytosis and this effect was abolished by IL-1ra treatment,
suggesting that the effect of LPS is, at least in part,
mediated by IL-1b. Interestingly, we would like to
emphasize that IL-1b is vital for resolving bacterial
infection caused by various pathogens [35,36]. Bacterial
infection results in an increased release of IL-1b,w h i c h
enhances phagocytic cell recruitment to infection sites
[36-38]. Moreover, during LPS-induced phagocytosis,
the production of the endogenous anti-inflammatory
cytokine IL-1ra is increased to balance possible cytotoxic
effects of IL-1b on neighboring tissues [39].
In vitro s t u d i e sh a v ed e s c r i b e dar o l ef o rN P Yi nt h e
modulation of various functions of macrophages, such
as adherence, chemotaxis, phagocytosis and superoxide
anion production [32,40-43]. Furthermore, we have also
identified a role for NPY in inhibition of nitric oxide
production and motility/migration by microglial cells
[9,16]. In the present study, we show that NPY inhibits
IL-1b-induced phagocytosis via Y1 receptor activation.
In agreement with our results, NPY has been shown to
decrease phagocytosis in older mice. Interestingly, in
these animals the release of IL-1b from peritoneal
macrophages was higher than that observed in younger
animals, and NPY also inhibited this effect [32]. The
role of NPY in regulation of phagocytosis seems to
depend also upon the particular pathogen studied and
their mechanisms of replication. In vitro studies have
shown that NPY inhibits engulfment of Leishmania
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Page 11 of 15Figure 7 HSP27 is present at the phagocytic cup. Representative confocal photomicrographs were taken to assess the role of LPS on
formation of the phagocytic cup. Untreated microglial cells (left panel) and cells treated with LPS (100 ng/ml) (right panel) revealed formation of
a cup-shaped structure engulfing an opsonized bead (open arrowhead). LPS treatment induced increased labeling of phosphorylated HSP27
throughout the cell cytoplasm and nucleus as well as in the cup. Cells were stained for phosphorylated HSP27 (in green), actin (in red) and
Hoechst 33342 (nuclei in blue). Opsonized beads are labeled in cyan blue. Scale bar 10 μm.
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Since infection of phagocytes is a crucial step for repli-
cation of Leishmania major, inhibiting phagocytosis
results in a protective action [44]. Moreover, the effect
of NPY may vary according to other parameters (e. g.
concentration, target cell, stimulus) and depends on
interactions between different cell types [30-32,45,46].
Recognition of pathogen-associated molecular patterns
triggers TLR signaling through myeloid differentiation
primary response gene 88 (MyD88) adapter molecule
and activation of mitogen-activated protein kinases
(MAPKs) and NF-B [47]. Furthermore, p38 MAPK sig-
naling has been implicated in phagocytosis carried out
by murine macrophages [48] and Drosophila hemocytes
[49]. Since cytoskeleton remodeling is vital for cell pha-
gocytosis, p38 could be a putative molecular target to
discern which signaling pathways are involved in this
process. There are several reports implicating p38 acti-
vation in phagocytosis, either as a consequence of pha-
gocytosis or as a necessary step to initiate this process
[48-50]. In fact, Blander and colleagues have shown that
the use of selective p38 inhibitors impairs the ability of
macrophages to phagocyte E. coli [51]. Moreover, upon
activation, phosphorylated p38 translocates to the
nucleus and phosphorylates MAPK-activated protein
kinase 2 (MK2) [52]. Cells deficient in MK2 are unable
to regulate actin reorganization and, therefore, to form
membrane protrusions [53]. MK2 modulation of phago-
cytosis may occur through the small heat shock protein
HSP25/27, since it regulates actin polymerization [54].
Phagocytosis can be triggered by different signals that
are recognized by different receptors, triggering different
signaling cascades. In our study, we focused on the role
of NPY on Fc receptor-mediated phagocytosis, the main
phagocytic process occurring in macrophages, a cell
type that shares close functional and morphological
resemblances to microglia. In fact, NPY reduced expres-
sion of Fc receptor on the cell surface of stimulated
microglia, thereby restraining the phagocytic capacity of
these cells under inflammatory challenge. In this regard,
NPY may modulate the phagocytic process in order to
maintain microglial activity close to a physiological rest-
ing/surveying state, even in the presence of a stimula-
tory/activating agent.
However, we should emphasize that our findings are
limited to the modulation of Fc receptor-mediated phago-
cytosis. Nevertheless, our data further highlight the puta-
tive anti-inflammatory and anti-phagocytic role of NPY,
and broaden our knowledge of the therapeutic value of
this neuropeptide in the treatment of CNS disorders.
Conclusions
In an inflammatory context, microglial cells become
strongly activated through a process that involves
Figure 8 NPY decreases FcgRIIA-myc expression on microglial
cells. (A) Densitometric quantification of western blots shows that
microglial cells treated with LPS (100 ng/ml) or with IL-1b (1.5 ng/
ml) increased FcgRIIA expression levels while NPY treatment (1 μM)
significantly inhibited this effect. (B) Representative confocal
photomicrographs demonstrate an inhibitory effect of NPY on LPS-
or IL-1b-induced FcgRIIA expression. Cells were stained for FcgRIIA-
myc (in red), CD11b (in green) and Hoechst 33342 (nuclei in blue).
Data are expressed as mean ± SEM (n = 4) and as a percentage of
control (*p < 0.05, using Bonferroni’s Multiple Comparison Test).
Scale bar 10 μm.
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and increase their ability to phagocytose. In our study,
NPY acting through Y1 receptors significantly restrained
microglial activation, thereby inhibiting LPS-induced Fc
receptor-mediated phagocytosis. Under physiological
conditions, resting-like cells show substantially low
levels of phosphorylated p38 MAPK and HSP27, thus
presenting limited phagocytic ability. The role of NPY
in the regulation of microglial cell phagocytosis is pro-
mising since this neuropeptide demonstrates a strong
inhibitory action on activated microglia-related
responses. While scientific research is commonly con-
ducted towards the regulation or improvement of
microglial phagocytosis, which appears limited or dys-
functional in chronic neurodegenerative diseases and
ageing [55], our findings could potentially lead to the
development of new therapeutic targets aiming at the
restriction of phagocytosis in pathological conditions
occurring in the brain.
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